B. Riley Issues Positive Outlook for MDGL Earnings

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) – Stock analysts at B. Riley lifted their Q1 2025 earnings estimates for Madrigal Pharmaceuticals in a report issued on Thursday, February 27th. B. Riley analyst M. Mamtani now anticipates that the biopharmaceutical company will earn ($2.71) per share for the quarter, up from their prior forecast of ($3.34). B. Riley currently has a “Strong-Buy” rating and a $422.00 price objective on the stock. The consensus estimate for Madrigal Pharmaceuticals’ current full-year earnings is ($23.47) per share. B. Riley also issued estimates for Madrigal Pharmaceuticals’ Q2 2025 earnings at ($1.83) EPS, Q3 2025 earnings at ($1.20) EPS, Q4 2025 earnings at ($0.32) EPS, FY2025 earnings at ($6.02) EPS, FY2026 earnings at $9.82 EPS and FY2027 earnings at $16.60 EPS.

Madrigal Pharmaceuticals (NASDAQ:MDGL) last released its quarterly earnings data on Wednesday, February 26th. The biopharmaceutical company reported ($2.71) earnings per share for the quarter, topping analysts’ consensus estimates of ($4.32) by $1.61. The business had revenue of $103.32 million during the quarter, compared to the consensus estimate of $97.81 million.

MDGL has been the subject of a number of other research reports. JMP Securities reaffirmed a “market outperform” rating and issued a $427.00 price target on shares of Madrigal Pharmaceuticals in a report on Friday, January 10th. Cantor Fitzgerald reissued a “neutral” rating on shares of Madrigal Pharmaceuticals in a research note on Wednesday, November 20th. HC Wainwright upped their price target on shares of Madrigal Pharmaceuticals from $400.00 to $405.00 and gave the stock a “buy” rating in a report on Thursday, February 27th. Finally, Citigroup lifted their price objective on shares of Madrigal Pharmaceuticals from $378.00 to $469.00 and gave the company a “buy” rating in a report on Thursday, February 27th. Two analysts have rated the stock with a sell rating, one has given a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $375.75.

Madrigal Pharmaceuticals Stock Performance

NASDAQ MDGL opened at $313.47 on Monday. The company has a debt-to-equity ratio of 0.15, a current ratio of 5.98 and a quick ratio of 5.93. The stock has a market capitalization of $6.84 billion, a PE ratio of -12.50 and a beta of -0.38. Madrigal Pharmaceuticals has a 1-year low of $189.00 and a 1-year high of $377.46. The business has a 50 day simple moving average of $322.98 and a two-hundred day simple moving average of $285.80.

Insider Activity at Madrigal Pharmaceuticals

In other news, Director James M. Daly sold 15,470 shares of the company’s stock in a transaction dated Thursday, February 27th. The shares were sold at an average price of $347.45, for a total transaction of $5,375,051.50. Following the transaction, the director now owns 1,912 shares in the company, valued at $664,324.40. This represents a 89.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Carole Huntsman sold 347 shares of the business’s stock in a transaction dated Friday, January 24th. The shares were sold at an average price of $335.24, for a total value of $116,328.28. Following the sale, the insider now owns 10,438 shares in the company, valued at approximately $3,499,235.12. The trade was a 3.22 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 20,560 shares of company stock valued at $6,932,536 over the last 90 days. Insiders own 22.80% of the company’s stock.

Institutional Trading of Madrigal Pharmaceuticals

Several large investors have recently made changes to their positions in the business. Nisa Investment Advisors LLC raised its holdings in shares of Madrigal Pharmaceuticals by 47.6% during the third quarter. Nisa Investment Advisors LLC now owns 211 shares of the biopharmaceutical company’s stock worth $45,000 after purchasing an additional 68 shares during the last quarter. Kohmann Bosshard Financial Services LLC acquired a new stake in Madrigal Pharmaceuticals during the fourth quarter worth about $70,000. Quest Partners LLC lifted its holdings in Madrigal Pharmaceuticals by 172.8% in the third quarter. Quest Partners LLC now owns 581 shares of the biopharmaceutical company’s stock valued at $123,000 after acquiring an additional 368 shares during the period. GF Fund Management CO. LTD. acquired a new position in Madrigal Pharmaceuticals in the 4th quarter worth about $141,000. Finally, BI Asset Management Fondsmaeglerselskab A S acquired a new stake in Madrigal Pharmaceuticals in the fourth quarter valued at approximately $164,000. 98.50% of the stock is owned by hedge funds and other institutional investors.

About Madrigal Pharmaceuticals

Madrigal Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH.